Status: Recruiting
Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
Participants needed: 336
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: National Society for Neurosonology and Cerebral CirculationUpdated: Apr 13, 2026Locations: 1Duration: 1 Year
Eligibility criteria
Age 18-85 ; [+2]
Individual intolerance or known hypersensitivity to a recombinant protein contai... [+2]